ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

Posted by Mark Dietrich on Apr 29th, 2024

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 13,400 shares, a drop of 30.6% from the March 31st total of 19,300 shares. Based on an average trading volume of 20,000 shares, the short-interest ratio is currently 0.7 days.

ProShares UltraShort Nasdaq Biotechnology Price Performance

Shares of NASDAQ BIS traded down $0.34 during mid-day trading on Friday, hitting $20.24. The company had a trading volume of 3,555 shares, compared to its average volume of 20,459. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $16.37 and a 1 year high of $26.51. The stock’s 50-day moving average price is $18.40 and its 200-day moving average price is $19.99.

ProShares UltraShort Nasdaq Biotechnology Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, March 27th. Shareholders of record on Thursday, March 21st were issued a dividend of $0.1586 per share. The ex-dividend date of this dividend was Wednesday, March 20th.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. IMC Chicago LLC bought a new position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,001 shares of the company’s stock, valued at approximately $271,000. IMC Chicago LLC owned 3.19% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

ProShares UltraShort Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.